Evaluation Of The Efficacy Of The Combination Of GLIZIGEN ® Oral Solution 1/Day And Vaginal Gel 1/Night For 2 Months In Patients With Cervical Intraepithelial Neoplasia Grade 1 (LSIL/CIN-1) Caused By High-Risk Human Papillomavirus (HPV-AR)

Conditions:   Papilloma Viral Infection;   CIN1;   LSIL, Low Grade Squamous Intraepithelial Lesion Interventions:   Dietary Supplement: Glizigen;   Other: Placebo Sponsors:   Catalysis SL;   Atika Pharma S.L. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials